Back

Semaglutide and cardiovascular outcomes by baseline chronic kidney disease status and albuminuria in type 2 diabetes and chronic kidney disease: results from the FLOW trial

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Clinical trial updates on the GLP-1 receptor agonist, semaglutide Renal Failure and Cardiovascular Disease ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Kenneth W Mahaffey

Stanford University Medical Center, Stanford (United States of America)

7 More presentations in this session

Presentation thumbnail
Atrial fibrillation and efficacy of semaglutide 2.4 mg in obesity-related HFpEF: A Patient Level Pooled analysis of STEP-HFpEF and STEP-HFpEF DM trials
Doctor M. Kosiborod (Kansas City, US)
Slides Video
Presentation thumbnail
Inflammation in obesity-related HFpEF: the STEP-HFpEF programme
Professor S. Verma (Toronto, CA)
Slides Video
Presentation thumbnail
STEP-HFpEF Program Echocardiography Substudy
Professor S. Solomon (Boston, US)
Slides Video
Presentation thumbnail
Effects of the GLP-1 receptor agonist, semaglutide, on heart failure outcomes: a pre-specified analysis of the FLOW trial in participants with type 2 diabetes and chronic kidney disease
Doctor R. Pratley (Orlando, US)
Slides Video
Presentation thumbnail
Effects of semaglutide on clinical events in heart failure with preserved ejection fraction: a pooled, participant-level analysis of SELECT, FLOW, STEP-HFpEF and STEP-HFpEF DM trials
Doctor M. Kosiborod (Kansas City, US)
Slides Video

Access the full session

Session thumbnail
Clinical trial updates on the GLP-1 receptor agonist, semaglutide
Video

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources